利索-全球专利检索

  1. Login
  2. Sign Up

Search Results

141 records (took 0.048 seconds)

    Boron-containing diacylhydrazines
    2.
    发明授权
    Boron-containing diacylhydrazines 有权

    公开(公告)号：US10851119B2

    公开(公告)日：2020-12-01

    申请号：US16580343

    申请日：2019-09-24

    Applicant: Intrexon Corporation

    Inventor： Sheela K. Chellappan ,  Robert E. Hormann ,  Inna Shulman

    IPC: C07F5/02 ,  C07F5/04 ,  C07F7/08

    Abstract: The present disclosure provides boron-containing diacylhydrazines having Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, R4, and R5 are defined as set forth in the specification. The present disclosure also provides the use of boron-containing diacylhydrazines is ecdysone receptor-based inducible gene expression systems. Thus, the present disclosure is useful for applications such as gene therapy, treatment of disease, large scale production of proteins and antibodies, cell-based screening assays, functional genomics, proteomics, metabolomics, and regulation of traits in transgenic organisms, where control of gene expression levels is desirable.

    Site-specific serine recombinases and methods of their use
    3.
    发明授权
    Site-specific serine recombinases and methods of their use 有权

    公开(公告)号：US10648003B2

    公开(公告)日：2020-05-12

    申请号：US16003266

    申请日：2018-06-08

    Applicant: Intrexon Corporation

    Inventor： Malla Padidam

    IPC: C12N15/90 ,  C12N9/00 ,  C12N9/22 ,  C12N15/52 ,  C12N15/79

    Abstract: The present invention provides a method for obtaining site-specific recombination in a eukaryotic cell, the method comprising providing a eukaryotic cell that comprises a first recombination attachment site and a second recombination attachment site; contacting the first and second recombination attachment sites with a prokaryotic recombinase polypeptide, resulting in recombination between the recombination attachment sites, wherein the recombinase polypeptide can mediate recombination between the first and second recombination attachment sites, the first recombination attachment site is a phage genomic recombination attachment site (attP) or a bacterial genomic recombination attachment site (attB), the second recombination site is attB or attP, and the recombinase is selected from the group consisting of a Listeria monocytogenes phage recombinase, a Streptococcus pyogenes phage recombinase, a Bacillus subtilis phage recombinase, a Mycobacterium tuberculosis phage recombinase and a Mycobacterium smegmatis phage recombinase, provided that when the first recombination attachment site is attB, the second recombination attachment site is attP and when the first recombination attachment site is attP, the second recombination attachment site is attB. The invention also describes compositions, vectors, and methods of use thereof, for the generation of transgenic cells, tissues, plants, and animals. The compositions, vectors and methods of the present invention are also useful in gene therapy applications.

    Improved Therapeutic Control of Proteolytically Sensitive, Destabilized Forms of Interleukin-12
    6.
    发明申请
    Improved Therapeutic Control of Proteolytically Sensitive, Destabilized Forms of Interleukin-12 审中-公开

    公开(公告)号：US20190062394A1

    公开(公告)日：2019-02-28

    申请号：US15767298

    申请日：2016-10-10

    Applicant: Intrexon Corporation

    Inventor： Ramya YARLAGADDA ,  Charles REED ,  Charles Andrew (Marshall) STEWART ,  Peter EMTAGE ,  Rutul SHAH ,  Timothy CHAN

    IPC: C07K14/54 ,  A61P35/00

    Abstract: The present invention relates to modified forms of IL-12. These modified forms of IL-12 may be engineered to have a shortened in vivo half-life compared and/or enhanced localization of biological effects compared to that of corresponding non-modified form of IL-12. Short half-life and membrane bound forms of IL-12 may provide greater therapeutic control for in vivo therapeutic delivery, in particular when used in combination with ligand inducible delivery of IL-12. Modified forms of IL-12 engineered to have shortened in vivo half-life and/or enhanced localization of biological effects include heterodimeric p35/p40, single chain and membrane bound forms of IL-12 wherein a naturally occurring IL-12 amino acid sequence is genetically modified to destabilize IL-12 tertiary structure/polypeptide folding and enhance susceptibility of the IL-12 molecule to in vivo proteolytic degradation.

    Site-specific serine recombinases and methods of their use
    8.
    发明授权
    Site-specific serine recombinases and methods of their use 有权

    公开(公告)号：US10081817B2

    公开(公告)日：2018-09-25

    申请号：US15338961

    申请日：2016-10-31

    Applicant: Intrexon Corporation

    Inventor： Malla Padidam

    IPC: C12N15/90 ,  C12N9/00 ,  C12N9/22 ,  C12N15/52 ,  C12N15/79

    CPC classification number: C12N15/907 ,  C12N9/00 ,  C12N9/22 ,  C12N15/52 ,  C12N15/79 ,  C12Y301/22

    Abstract: The present invention provides a method for obtaining site-specific recombination in a eukaryotic cell, the method comprising providing a eukaryotic cell that comprises a first recombination attachment site and a second recombination attachment site; contacting the first and second recombination attachment sites with a prokaryotic recombinase polypeptide, resulting in recombination between the recombination attachment sites, wherein the recombinase polypeptide can mediate recombination between the first and second recombination attachment sites, the first recombination attachment site is a phage genomic recombination attachment site (attP) or a bacterial genomic recombination attachment site (attB), the second recombination site is attB or attP, and the recombinase is selected from the group consisting of a Listeria monocytogenes phage recombinase, a Streptococcus pyogenes phage recombinase, a Bacillus subtilis phage recombinase, a Mycobacterium tuberculosis phage recombinase and a Mycobacterium smegmatis phage recombinase, provided that when the first recombination attachment site is attB, the second recombination attachment site is attP and when the first recombination attachment site is attP, the second recombination attachment site is attB. The invention also describes compositions, vectors, and methods of use thereof, for the generation of transgenic cells, tissues, plants, and animals. The compositions, vectors and methods of the present invention are also useful in gene therapy applications.

Patent Agency Ranking